KR20080041669A - 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물 - Google Patents

매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물 Download PDF

Info

Publication number
KR20080041669A
KR20080041669A KR1020087004755A KR20087004755A KR20080041669A KR 20080041669 A KR20080041669 A KR 20080041669A KR 1020087004755 A KR1020087004755 A KR 1020087004755A KR 20087004755 A KR20087004755 A KR 20087004755A KR 20080041669 A KR20080041669 A KR 20080041669A
Authority
KR
South Korea
Prior art keywords
dose
proportional
less
auc
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087004755A
Other languages
English (en)
Korean (ko)
Inventor
아미르 에이치. 쇼재이
마이클 페닉
Original Assignee
샤이어 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37668083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20080041669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 샤이어 엘엘씨 filed Critical 샤이어 엘엘씨
Publication of KR20080041669A publication Critical patent/KR20080041669A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087004755A 2005-07-28 2006-07-27 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물 Withdrawn KR20080041669A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28
US60/702,982 2005-07-28

Publications (1)

Publication Number Publication Date
KR20080041669A true KR20080041669A (ko) 2008-05-13

Family

ID=37668083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087004755A Withdrawn KR20080041669A (ko) 2005-07-28 2006-07-27 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물

Country Status (18)

Country Link
US (1) US20070048371A1 (enExample)
EP (1) EP1909766B1 (enExample)
JP (2) JP5726401B2 (enExample)
KR (1) KR20080041669A (enExample)
CN (1) CN101252917A (enExample)
AR (1) AR054595A1 (enExample)
AU (1) AU2006275718B8 (enExample)
BR (1) BRPI0615989B8 (enExample)
CA (1) CA2616181C (enExample)
DK (1) DK1909766T3 (enExample)
ES (1) ES2566395T3 (enExample)
IL (1) IL188980A0 (enExample)
NO (1) NO20081038L (enExample)
NZ (1) NZ565649A (enExample)
RU (1) RU2435573C2 (enExample)
TW (1) TW200744672A (enExample)
WO (1) WO2007016284A2 (enExample)
ZA (1) ZA200801575B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916163D0 (en) * 2009-09-15 2009-10-28 Shire Llc Prodrugs of guanfacine
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
US20110313046A1 (en) * 2010-06-11 2011-12-22 Ermer James Combination therapy with lisdexamphetamine and extended release guanfacine
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
US9180104B2 (en) * 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
AU2014240988B9 (en) 2013-03-13 2019-01-03 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
AU2016368622B2 (en) * 2015-12-08 2022-09-08 Ardea Biosciences, Inc. Pharmaceutical composition comprising a potent inhibitor of URAT1
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗ｈｃｖ活性を有する薬剤
NZ746669A (en) * 2016-04-20 2022-10-28 New Frontier Labs Llc Azelaic acid esters in the treatment of insulin resistance
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
JP2023035359A (ja) * 2021-09-01 2023-03-13 東和薬品株式会社 グアンファシン製剤
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2003051340A1 (en) * 2001-12-19 2003-06-26 Astrazeneca Ab New film coating
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2003224794A1 (en) * 2002-03-29 2003-10-13 Alza Corporation Volume efficient controlled release dosage form
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Also Published As

Publication number Publication date
TW200744672A (en) 2007-12-16
AU2006275718B2 (en) 2012-10-04
BRPI0615989B8 (pt) 2021-05-25
US20070048371A1 (en) 2007-03-01
CA2616181C (en) 2015-02-17
AU2006275718A1 (en) 2007-02-08
AR054595A1 (es) 2007-06-27
RU2008102911A (ru) 2009-09-10
ES2566395T3 (es) 2016-04-12
BRPI0615989A2 (pt) 2011-05-31
JP2009502951A (ja) 2009-01-29
WO2007016284A2 (en) 2007-02-08
RU2435573C2 (ru) 2011-12-10
JP5726401B2 (ja) 2015-06-03
IL188980A0 (en) 2008-08-07
CN101252917A (zh) 2008-08-27
BRPI0615989B1 (pt) 2020-05-26
CA2616181A1 (en) 2007-02-08
EP1909766B1 (en) 2016-03-16
EP1909766A2 (en) 2008-04-16
ZA200801575B (en) 2008-12-31
AU2006275718B8 (en) 2012-11-01
WO2007016284A3 (en) 2007-03-29
DK1909766T3 (en) 2016-04-04
NZ565649A (en) 2011-03-31
JP2012229253A (ja) 2012-11-22
AU2006275718A8 (en) 2012-11-01
NO20081038L (no) 2008-04-23

Similar Documents

Publication Publication Date Title
JP2012229253A (ja) 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形／組成物
DE60224194T2 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
AU2008207707A1 (en) Sustained release ranolazine formulations
KR20030011805A (ko) 스타부딘을 함유하는 서방성 비들렛
CA2793222C (en) Stabilized formulations of cns compounds
WO2010046932A2 (en) Extended release pharmaceutical composition of minocycline and process thereof
US20070298098A1 (en) Controlled Release Compositions Comprising Levetiracetam
AU2014295098A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2006088864A1 (en) Controlled release compositions comprising levetiracetam
US20100285119A1 (en) Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same
EP2298290A1 (en) Controlled release composition comprising levetiracetam
CA2918528A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
CN110913843B (zh) 药物组合物
US10335376B2 (en) Raloxifene sprinkle composition
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
HK1119400A (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin
CA2812968A1 (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid